top of page

Verastem licenses Duvelisib from Infinity Pharmaceuticals for $28 million

Verastem and Infinity Pharmaceuticals have entered into a license agreement under which Verastem licensed exclusive worldwide rights to develop and commercialise Infinity’s oncology product candidate duvelisib.




Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page